This study was performed to assess the atrial defibrillation threshold in patients with recurrent atrial fibrillation (AF) using repeated internal cardioversion.
Atrial fibrillation (AF) has been shown to deteriorate hemodynamics (1) (2) (3) , to lead to systemic embolism including stroke (1, 2) and to a twofold risk of cardiac mortality (1, 4) . Associated structural changes of the atria foster the arrhythmia (2) . Therefore, prompt restoration of sinus rhythm is desirable in principle. Several therapeutic options have been devised for restoration and maintenance of sinus rhythm, including pharmacological, external and internal conversion, surgical treatment, atrial pacemaker implantation, high-frequency ablation of foci and, most recently, an implantable atrial defibrillator (1, 2, (5) (6) (7) (8) (9) (10) (11) (12) (13) . Despite recent technical advances, such as optimized shock morphology and electrode position in internal cardioversion (11,14 -18) , some concerns still exist with this new mode of treatment.
Relatively high energy requirements (10,16,19 -21) and consequent pain perception (12, 17, (22) (23) (24) currently limit the use of an automatic atrial defibrillator to patients with low initial atrial defibrillation thresholds (1, 2, 5, 12, 20, 25) .
Thus, it was the aim of the present study to assess defibrillation thresholds for repeated internal cardioversion with respect to patients' parameters. By proving the hypothesis that shortened AF duration lowers defibrillation thresholds for internal cardioversion, more patients might be considered for an implantable atrial defibrillator (2,16,20,24 -26) .
METHODS
Patients. In the present study, patients who underwent repeated internal cardioversion were included. Of 80 patients to undergo this procedure for chronic AF, sinus rhythm could be successfully restored in 74, as previously reported (27) .
All 74 patients were on sotalol (189 Ϯ 63 mg/day); 35 had a relapse of AF after a mean follow-up of 14.2 Ϯ 6.9 (range 12.5 to 36) months. Eighteen of these patients requested a second internal cardioversion, and they formed the basis of this study. The 18 patients (58 Ϯ 6 years of age; 4 women, 14 men, body weight 75 Ϯ 11 kg, body height 170 Ϯ 12 cm; left atrial size 58 Ϯ 4 mm) had suffered chronic AF for 175 Ϯ 113 days (range 30 to 500 days) before their first cardioversion. The underlying heart disease was diagnosed as coronary artery disease in 5 patients, hypertension in 4, valvular disease in 4, lone or idiopathic AF in 3 and dilated cardiomyopathy in 2 patients. Pharmacological conversion attempts had been performed in 14 patients (72%) before initial internal cardioversion without success in eight patients (57%); antiarrhythmic medication did not prevent recurrent AF in the other six patients.
According to the study protocol (27) , approved by the Ethics Committee of the Technical University of Munich, patients 21 to 75 years old were enrolled if the following selection criteria were fulfilled:
1. chronic atrial fibrillation of at least 14 days duration, documented by serial electrocardiogram (ECG); and 2. effective anticoagulation with warfarin for at least 14 days (INR [international normalized ratio] 2.5 to 4.2).
Patients were excluded from the study because of:
1. evidence of digitalis toxicity; 2. abnormal electrolyte concentrations; 3. hyperthyroidism; 4. an acute myocardial infarction within the past six weeks; or 5. a prior history of embolism.
Clinical examination was performed and medical history was taken. In all patients, routine 12-lead ECG, 24-h Holter monitoring, chest roentgenogram, routine laboratory including thyroid parameters and M-mode and Doppler echocardiography were performed. A transesophageal echocardiography was obtained if clinically indicated. Benefits and risks of the study were discussed with the patients and informed consent was obtained.
Protocol for internal cardioversion. The protocol was carried out as in previous studies (27) (28) (29) . Two temporary 6 F catheters (Elecath; Electro-Catheter Corp., Rahway, New Jersey), with an active surface area of 2.62 cm 2 consisting of 10 parallel stainless steel rings, were inserted into the femoral vein and positioned in the right atrium and either the distal coronary sinus or the left pulmonary artery.
Lead position was randomized: seven patients underwent cardioversion and had the catheters in the right atrium and coronary sinus, and 11 patients had the catheters in the right atrium and pulmonary artery.
Internal cardioversion was performed either in the intensive care unit or in the electrophysiology laboratory. The patients were sedated orally with 2.5 to 5 mg diazepam. Immediately before cardioversion, 1 mg midazolam was administered intravenously; in two anxious patients, 5 mg midazolam were given. No antiarrhythmic drug was administered within 48 h before or during the procedure.
The defibrillation threshold was defined as the lowest shock energy that converted AF into sinus rhythm. Biphasic, two-capacitor shocks of 3 ms/3 ms with phases separated by a delay of 0.2 ms were used. The shocks were delivered by an external defibrillator (Ventritex HVS-02; Ventritex, Sunnyvale, California) and synchronized to the R-wave. In order to ensure R-wave synchronization, the ECG was amplified and filtered by a custom-built, variablegain ECG amplifier. Special circuitry prevented shock delivery when the cycle length was shorter than 500 ms (30) . Oxygen saturation was monitored using a pulse oxymeter, and the blood pressure was measured every 10 min. Beginning with a test shock of 60-V intensity, the voltage was increased in 40-V steps until cardioversion was achieved. Criteria for discontinuation were patient discomfort, complications such as induction of proarrhythmia or major bleedings, or achieving the maximum voltage of 580 V. Between unsuccessful defibrillation attempts, at least 1 min before the next shock was applied. During the study, the 12-lead ECG and intraatrial signals were recorded and stored (EP Lab, version 6.0; Quinton Electrophysiology, Inc., Ontario, Canada).
The delivered voltage, current, and morphology for each shock were recorded using a Macintosh computer and customized LabVIEW software (National Instruments, Austin, Texas). The delivered voltage and current waveforms were integrated to obtain energy, and impedance was calculated from the peak voltage and current. Patients were asked to quantify their level of perceived pain by means of a scale ranging from 0 (not felt) to 10 (intolerable) after each shock applied.
Follow-up evaluation. Upon experiencing symptoms suggestive of recurrent AF, patients were asked to return for a 12-lead ECG. Otherwise, follow-ups were performed at 1, 3, 6, 9 and 12 months after cardioversion. All patients were treated with at least 80 mg bid sotalol (mean daily dose for these 18 patients 175 Ϯ 55 mg, range 160 to 400 mg) after effective cardioversion to sinus rhythm. Angiotensin converting enzyme inhibitors, diuretics and digitalis were continued based on the clinical status of the patients. Anticoagulation was continued after cardioversion and was stopped only in patients who remained in sinus rhythm for 4 weeks.
Protocol for repeated internal cardioversion. Before the second internal cardioversion, no patient had an attempt at Table 1 ). In the first procedure, the defibrillation threshold for the right atrium-coronary sinus vector was lower than for the right atrium-pulmonary artery vector (for the first cardioversion, p ϭ 0.018; for the second cardioversion, NS).
Patient characteristics.
Of the 18 patients undergoing repeated internal cardioversion of recurrent AF, body mass index remained stable throughout the study (26 Ϯ 0.8 kg/m 2 ). The mean echocardiographically determined longitudinal left atrial diameter was 58 Ϯ 4 mm (range 53 to 60 mm) at the first and 57 Ϯ 3 mm (range 51 to 60 mm) at the second cardioversion (NS). The duration of atrial fibrillation (175 Ϯ 113 vs. 34 Ϯ 25 days, p ϭ 0.002) was considerably longer at the time of the first cardioversion than at the second (Table 1, Fig. 2 ).
Correlation of defibrillation thresholds and patient parameters. There was a significant correlation of energy requirements and duration of AF before the first cardioversion with the right atrium-coronary sinus vector (p ϭ 0.033, r 2 ϭ 0.629; Fig. 3 ) and with the right atrium-pulmonary artery vector (p ϭ 0.050, r 2 ϭ 0.210; Fig. 3 ). For the second cardioversion with overall significantly shorter durations, no such correlation was observed (p ϭ 0.230, r 2 ϭ 0.272 and p ϭ 0.668, r 2 ϭ 0.004, respectively). There was no correlation between energy requirements and either left atrial size or body mass index (NS). In terms of symptoms, the pain Uni-and multivariate analysis of patient parameters and defibrillation threshold. Only the duration of AF before the first and second cardioversion was significant (p ϭ 0.0007). Age, body mass index, left atrial diameter and underlying heart disease were not statistically significant.
Long-term clinical outcome.
On an intention-to-treat basis, 11 of 18 patients successfully treated with repeated internal cardioversion remained in sinus rhythm after a mean follow-up of 11.4 Ϯ 4 months (range 11 to 18 months; Table 1 ). In three patients, AF recurred after 7, 14 and 30 days. After their first internal cardioversion, AF had recurred after 3, 1 and 30 days, respectively. In another three patients, AF recurred after 3, 14 and 30 days after the first cardioversion, but 60 days after the second one. One patient remained in sinus rhythm for 30 days after the first and for 45 days after the second cardioversion.
Complications. There were no complications observed in the 18 patients of this present study.
DISCUSSION
The present study demonstrates that compared with the first intervention, despite nearly identical impedance, less energy is required when internal cardioversion of AF is performed a second time. In addition, sinus rhythm persists for a longer period afterwards (Table 1) . Furthermore, AF duration before cardioversion might be a critical parameter, which is in keeping with the majority of literature reports available on this issue (2, 10, 25, 31) . In this study, a significant correlation was seen between defibrillation thresholds and duration of chronic AF (range from 14 to 500 days) in patients undergoing internal cardioversion for the first time. In patients undergoing cardioversion a second time shortly after the onset of AF (7 to 66 days, mean 34 Ϯ 25 days) and with no other measured patient parameter having changed, no such correlation is seen. This indicates that in chronic AF, partially reversible changes over time may lead to increases in energy requirements.
Influence of AF duration on defibrillation threshold.
These findings do not point to the quality of the electrical field as the decisive aspect for cardioversion, as has been noted until recently (1, 11, 12, 14, 21, 22, 24, 27, 32) but rather to cellular and subcellular aspects brought about over time by the arrhythmia itself (2, 5, (33) (34) (35) (36) . Atrial atrophy, fibrosis and dilation are some of the consequences observed in chronic AF (2), which had been formerly viewed as both its cause and result (1,2,5,34 -36) . Apparently, both electrical changes, such as shortened fibrillatory cycle length and shortened effective refractory period, and organic lesions, as already mentioned, impact on the defibrillation threshold. Electrical phenomena, starting with a shortening of the atrial refractory period, become full-blown within a few days Ammer et al. November 1, 1999 November 1, :1569 Repeated Internal Cardioversion of chronic AF and can be assumed to be reversible up to one week after restoration of sinus rhythm (33) . With chronic persistence of AF, however, these phenomena can impinge on the type of AF (2, 33, 34) and thus influence its reversibility (10, 21, 25, 27, 31, 33) . By contrast, organic alterations, such as insulating collagenous septa between atrial muscle bundles (8), develop over months and years (34) , but once present, they are irreversible, rendering restoration and maintenance of sinus rhythm more difficult (1, 7) . According to both the pathophysiological aspects and the clinical data of the current study as well as others (10, 22, 24, 25, 31, 33) , and taking all the possible sequelae of AF into consideration (1) (2) (3) (4) (5) , an early cardioversion of AF should be generally strived for. Comparably low energy requirements caused by a lower defibrillation threshold after a comparably short AF duration, and the aim of preventing occurrences or worsening of the above-mentioned AFrelated phenomena, support this view.
Influence of defibrillation threshold on pain perception.
Recent studies have shown variable response to intracardiac shocks on pain perception (12, 16, 20, 22, 37) . In our population, there seems to be a strong correlation between energy applied and pain perceived (Fig. 4) . Our previous findings that energy might determine shock effectiveness but peak voltage determines pain perception (18) are supported in this study. Thus, expanding the shock width may afford a reduction in leading edge voltage, in order to improve tolerability and to maintain efficacy of internal cardioversion (18, 37) .
Influence of defibrillation vector on defibrillation threshold. The selection of the catheter site in the right atrium and coronary sinus or in the right atrium and left pulmonary artery determining the shock vector seems to have an effect on efficacy and on tolerability of internal cardioversion. As reported previously, the right atrium-coronary sinus vector requires lower energy thresholds compared with the right atrium-pulmonary artery vector (27, 38, 39) . This beneficial effect on energy implies a favorable effect on tolerability of internal cardioversion, which can be seen in our group of patients undergoing cardioversion for the first time (p ϭ 0.073). In the second cardioversion, a trend favoring the right atrium-coronary sinus vector can be appreciated (p ϭ 0.102, NS).
Influence of antiarrhythmic medication on defibrillation threshold. In order to maintain sinus rhythm, patients were treated with oral sotalol (mean daily dose 175 Ϯ 55 mg, range 160 to 400 mg) based on prior experience (37, 39) . In this study, we tried to eliminate the effect of sotalol on the defibrillation threshold by discontinuing medication at least 48 h before cardioversion, which equals four times the elimination half-life of sotalol of 12 h (40,41). None of the 18 patients had renal insufficiency. So far, sotalol has been shown to be effective in lowering the defibrillation threshold in animals (42) and patients with acute atrial fibrillation (43) only when given concurrently with a low-energy shock. By contrast to our study, sotalol was given intravenously (5 mg/kg in canines, 1.5 mg/kg in humans) and did not reduce the threshold in patients with chronic AF, but ventricular pacing was required. None of our 18 patients required ventricular pacing during or after the cardioversion, consistent with the prior termination of sotalol medication. However, plasma levels of sotalol were not obtained.
Clinical implications and conclusions. Initially high defibrillation thresholds could be reduced upon early renewed shock delivery, presumably due to shorter duration of AF episodes (24, 25) . The reported favorable alterations in the atrial defibrillation threshold for repeated internal cardioversion could potentially improve the pain perception associated with intracardiac shock delivery; consequently, the number of patients could increase in whom an implantable device might be considered (2,11,12,18,20,25). 
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